DURECT Corp at Oppenheimer Healthcare Conference (Virtual) Transcript
Okay, great. Hi, everyone. My name is Francois Brisebois. I'm one of the biotech analysts at Oppenheimer. Thanks for joining on day three of the healthcare conference. I know it has been messy in the market and with the weather as well for some people so appreciate you taking the time to join us today.
The next presenter here would be DURECT Corporation. DURECT is a company that we cover at AHFIRM with an outperform rating, a big, big year for the company, with important data readout later this year in alcoholic hepatitis or alcohol-associated hepatitis. I think we've changed the name to that.
So from the team, we have CEO, Jim Brown; we have CMO, Chief Medical Officer, Dr. Norman Sussman; we have CFO, Tim Papp; and we also have Senior VP -- sorry, yes, Senior VP, Business Development and Commercial with Keith Lui. So -- which should be helpful to have everyone on here.
Questions & Answers
So what we'll do in terms of
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |